Reading IDYA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IDYA free→Reading IDYA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IDYA free→QuarterlyIQ Insights · IDYA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. Underwriting Agreement On June 8, 2026, IDEAYA Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC and Cantor Fitzgerald & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 5,555,556 shares (the “Shares”) of…
Other Events. Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer On June 3, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced it has entered into a clinical collaboration with F. Hoffmann-La Roche Ltd (“Roche”) to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class PRMT5 inhibitor, in combination with Roche’s RG6505, a pan-RAS inhibitor, in patients with pancreatic ductal adenocarcinoma (“PDAC”) that carry an MTAP deletio…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'fair' to 'full'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.